Tiziana seeks partner in Asia to enhance hepatocellular carcinoma treatment
Tiziana seeks partner in Asia to enhance hepatocellular carcinoma treatment
05 May 2021 | News
Source credit: Shutterstock
Tiziana Life Sciences plc, a UK based biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan KK, Pharma Team, for a strategic business development plan to identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients.
Previously, Tiziana successfully completed a Phase 2 clinical trial with orally administered Milciclib in sorafenib-resistant or intolerant HCC patients. The clinical data, presented at the American Society of Clinical Oncology (ASCO), demonstrated that the treatment was well-tolerated and produced clinical activity. Recently, a patent covering the use of Milciclib in combination with a tyrosine kinase inhibitor (TKI) or other drugs was granted.